Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and $8 price target on IntelliPharmaCeutics International (NASDAQ: IPCI) noting the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Intellipharmaceutics (IPCI) Not Required to Conduct Rexista Oxycodone XR Phase 3 if Oxycontin Bioequivalence DemonstratedMay 21, 2015 8:04 AM Intellipharmaceutics Intends to Accelerate its Rexista(TM) Oxycodone XR Development Program on the Basis of Positive Feedback from the FDAMay 21, 2015 8:02 AM